Current immunotherapies predominantly target the effector arm of the immune system, focusing on enhancing T-cell responses through approaches such as immune checkpoint blockade (e.g., PD-L1 antibodies), activation of adaptive immune responses via tumor vaccines, or the use of engineered T cells (e.g., CAR-T therapy) [42]. Here, CD274 is linked to neoplasm.